web analytics
Pubblicità

di Giancarlo Nicoli

As soon as I started to publish the weekly “Dendreon Notable Links”, I got my website hacked! I spent the last three weeks figuring out how to clean it and – especially – how to keep it clean. It’s five days (and counting) scoprire.biz is actually virus free. Now let’s jump in.

26 April 2012 – Video
This one is an earlier link in fact, I saved it for publication as soon as my website was ready.
Michael receiving 2nd leukaphereis treatment:
http://www.youtube.com/watch?v=sg4VaCTj2mM

Some catch-up…
Monday, 7 May 2012
Dendreon Reports Net PROVENGE Product Revenues of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth:
http://finance.yahoo.com/news/dendreon-reports-net-provenge-product-203000496.html

Monday, 7 May 2012
Dendreon’s CEO Discusses Q1 2012 Results – Earnings Call Transcript:
http://seekingalpha.com/article/567681-dendreon-s-ceo-discusses-q1-2012-results-earnings-call-transcript

Thursday, 9 May 2012
The end game for Biotech – HGSI (DNDN?) – by guam2009lt
http://www.investorvillage.com/smbd.asp?mb=971&mn=437288&pt=msg&mid=11709638

Friday, 11 May 2012
Dendreon Management Presents at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference (Transcript):
http://seekingalpha.com/article/583091-dendreon-management-presents-at-deutsche-bank-securities-inc-
37th-annual-health-care-conference-transcript

Saturday, 12 May 2012
Sipuleucel-T Stimulates Response in Localized Setting, Study Finds:
http://www.onclive.com/publications/Oncology-live/2012/April-2012/
Sipuleucel-T-Stimulates-Response-in-Localized-Setting-Study-Finds

Tuesday, 15 May 2012
To be held on Sunday, May 20, 2012 3:30 PM-5:30 PM
Prostate Cancer: Advanced I Podium
Dendreon Corporation
683: Estimating the overall survival benefit of sipuleucel-T in the IMPACT trial accounting for crossover treatment in control subjects with autologous immunotherapy generated from cyropreserved cells
Leonard Gomella
Chadi Nabhan
Todd DeVries
James Whitmore
Mark Frohlich
Daniel George
http://www.aua2012.org/abstracts/printpdf.cfm?ID=683

Tuesday, 15 May 2012
To be held on Monday, May 21, 2012 10:30 AM-12:30 PM
Prostate Cancer: Advanced III Moderated Poster
Dendreon Corporation
953: Sipuleucel-T in African Americans: a subgroup analysis of three phase 3 trials of sipuleucel-T in metastatic castrate resistant prostate cancer
David G. McLeod
David I. Quinn
Jennifer Cullen
James B. Whitmore
Rockville, MD
http://www.aua2012.org/abstracts/printpdf.cfm?ID=953

Wednesday, 16 May 2012
Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society of Clinical Oncology Annual Meeting:
http://files.shareholder.com/downloads/DNDN/
1878048609x0x570219/f1b5abf8-e3f9-40da-ba7a-d88f995bdaff/
DNDN_News_2012_5_16_General.pdf

Very important data overall.
Abstract #4684: Overall Survival (OS) Benefit with Sipuleucel-T by Baseline PSA; An Exploratory Analysis From the Phase 3
IMPACT Trial, basically says that the earlier a patient gets Provenge, the better are his survival chances.

@ @ @

DNDN website:
http://www.dendreon.com/

Provenge website:
http://provenge.com/

All links are verified and working at date of publication.

Comments

Comments are closed.

%d bloggers like this: